ClinicalTrials.gg
RecruitingNCT07616037Updated May 29, 2026

Efficacy of a GLP-1/FGF21 Dual Agonist for Treating PCOS

A Phase 2 interventional study of GLP-1/FGF21 dual agonist (HEC88473) in PCOS (Polycystic Ovary Syndrome), sponsored by Shanghai Zhongshan Hospital. Recruiting at 1 site in China. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-05-29.

Sponsored by Shanghai Zhongshan Hospital · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years to 40 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 107 studies in Polycystic Ovary Syndrome with a site in China — 29 open to participants now, 33 under way, none of them phase 3. Polycystic Ovary Syndrome · China.

Planned enrollment
81st of 86
30 · median 100
Started
2026
with 6 others
Phase 2
6 of 107
3 open now
Primary completion
2027-06
later than 22 of 32 live
Registered
99th of 107
by date
Lead sponsor
5 of 107
Shanghai Zhongshan Hospital

Among the 107 studies in Polycystic Ovary Syndrome with a site in China, this one is the 81st largest by planned enrollment of the 86 interventional ones that give a count, is one of 7 that started in 2026, is one of 6 in phase 2, reaches primary completion later than 22 of the 32 other live ones, and was the 99th registered.

Polycystic Ovary Syndrome

959 studies on the registry are indexed under Polycystic Ovary Syndrome; 176 are open to participants now.

Browse Polycystic Ovary Syndrome studies →

Open to participants now

29 of the 107 studies in Polycystic Ovary Syndrome with a site in China are open now. Recruiting first, the newest first:

23 more — sign in →

All 29 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 120 Polycystic Ovary Syndrome studies recruiting now, 11 (9%) set no upper age limit and 106 (88%) stop at 75 or younger; 23 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 40 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 107 studies in Polycystic Ovary Syndrome with a site in China, or all of them as a file.
02

Study summary

Polycystic ovary syndrome (PCOS) is the most common reproductive endocrine and metabolic disorder among women of reproductive age. It is characterized by oligo-ovulation or anovulation, clinical and/or biochemical hyperandrogenism, and polycystic ovarian morphology. In addition, PCOS is frequently accompanied by multiple metabolic abnormalities, including insulin resistance, obesity, impaired glucose tolerance, and dyslipidemia. Clinical studies have demonstrated that treatment with glucagon-like peptide-1 receptor agonists (GLP-1RAs) in women with PCOS results in significant weight reduction, decreased free testosterone levels, improvement in menstrual regularity, and increased clinical pregnancy rates. Fibroblast growth factor 21 (FGF21) has been shown to enhance insulin sensitivity, promote fatty acid oxidation, and improve lipid distribution.

HEC88473 is a novel long-acting dual agonist targeting both the glucagon-like peptide-1 (GLP-1) receptor and the fibroblast growth factor 21 (FGF21) receptor. This study is initiated to evaluate the clinical efficacy of HEC88473 in women with PCOS and to explore its potential as a new therapeutic option for the management of PCOS.

03

Conditions studied

  • PCOS (Polycystic Ovary Syndrome)

Keywords

  • PCOS
  • GLP-1/FGF21 dual agonist
04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 18 and 40 years.
  • Female.
  • No plan for pregnancy from the time of signing the until 2 months after the last dose of study drug, and willingness to use study-approved methods during this period.
  • Fulfillment of at least two of the diagnostic criteria for PCOS according to the 2023 International Guideline, including:

    1. Irregular menstrual cycles:

      1-3 years after menarche: cycle length \<21 days or >45 days; ≥3 years after menarche to perimenopause: cycle length \<21 days or >35 days, or fewer than 8 menstrual cycles per year; ≥1 year after menarche: any cycle >90 days;

    2. Polycystic ovarian morphology: at least one ovary with ≥20 antral follicles (diameter \<10 mm), confirmed by transvaginal or transrectal pelvic ultrasonography;
    3. Hyperandrogenism: biochemical hyperandrogenism (total testosterone >1.67 nmol/L) or clinical hyperandrogenism (modified Ferriman-Gallwey [mFG] score >4).

Exclusion criteria

Exclusion Criteria:

  • Use of hormonal within 2 months prior to screening.
  • History of acute or chronic pancreatitis or pancreatic injury.
  • Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2A or 2B.
  • History of type 1 or type 2 diabetes mellitus.
  • Presence of other endocrine disorders that may cause polycystic ovarian morphology, such as 21-hydroxylase deficiency, pituitary prolactinoma, hypothyroidism, or Cushing's syndrome.
  • Current use of other medications known to affect reproductive function, with discontinuation less than 2 months prior to screening, including GnRH agonists or antagonists, anti-androgens, and gonadotropins.
  • Current use of other medications that may affect metabolism, with discontinuation less than 1 month prior to screening, including metformin, thiazolidinediones, and SGLT2 inhibitors.
  • History of bariatric surgery within the past 12 months.
  • Treatment with GLP-1 receptor agonists within the past 12 months.
  • Pregnancy or lactation.
  • Presence of other serious diseases of major organs such as the heart, liver, or kidney, or any .
  • Any other condition that, in the investigator's opinion, may interfere with the evaluation of efficacy or safety or render the participant unsuitable for this study.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    HEC88473 Treatment in Women With PCOS

    To evaluate the longitudinal changes in androgen metabolism in women with polycystic ovary syndrome (PCOS) during treatment with the GLP-1/FGF21 dual agonist HEC88473.

    Drug: GLP-1/FGF21 dual agonist (HEC88473)

Interventions

  • DrugGLP-1/FGF21 dual agonist (HEC88473)

    Drug page: Glucagon-Like Peptide 1Studies of Glucagon-Like Peptide 1Glucagon-Like Peptide 1 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    GLP-1/FGF21 dual agonist (HEC88473) will be administered by subcutaneous injection once weekly. The starting dose is 15 mg for 3 consecutive weeks. If well tolerated, the dose will be escalated to 30 mg for an additional 3 weeks, followed by further escalation to 45 mg for 18 weeks, provided tolerability is maintained.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Free Androgen Index Over 24 Weeks of Treatment

    Longitudinal changes in free androgen index from baseline at each scheduled follow-up visit during the 24-week treatment period.

    Time frame: Baseline to Week 24 (assessed at scheduled follow-up visits).

Secondary outcomes

  1. Change in the Number of Spontaneous Menstrual Cycles During the 24-Week Treatment Period Compared With the 24-Week Pre-treatment Period

    Comparison of the number of spontaneous menstrual cycles during the 24-week intervention period with those during the 24-week period prior to treatment initiation.

    Time frame: 24 weeks before treatment initiation to 24 weeks after treatment initiation.

  2. Change From Baseline in Bilateral Antral Follicle Count (Diameter <10 mm) at Week 24

    Change from baseline in the total number of antral follicles with a diameter \<10 mm in both ovaries after 24 weeks of treatment.

    Time frame: Baseline to Week 24.

  3. Change From Baseline in Bilateral Ovarian Volume at Week 24

    Change from baseline in the total ovarian volume of both ovaries after 24 weeks of treatment.

    Time frame: Baseline to Week 24.

  4. Change From Baseline in Serum AMH at Week 24

    Change from baseline in serum levels of anti-Müllerian hormone (AMH) after 24 weeks of treatment.

    Time frame: Baseline to Week 24.

  5. Change From Baseline in Serum Total Testosterone at Week 24

    Change from baseline in serum levels of total testosterone after 24 weeks of treatment.

    Time frame: Baseline to Week 24.

  6. Change From Baseline in Serum DHEA-S at Week 24

    Change from baseline in serum levels of dehydroepiandrosterone sulfate (DHEA-S) after 24 weeks of treatment.

    Time frame: Baseline to Week 24.

  7. Change From Baseline in Serum SHBG at Week 24

    Change from baseline in serum levels of sex hormone-binding globulin (SHBG) after 24 weeks of treatment.

    Time frame: Baseline to Week 24.

  8. Change From Baseline in HOMA IR Index at Week 24

    Change from baseline in insulin resistance assessed by the HOMA Insulin Resistance index (calculated from fasting plasma glucose in mmol/L × fasting serum insulin in μU/mL/22.5) after 24 weeks of treatment.

    Time frame: Baseline to Week 24.

  9. Change From Baseline in Lipid Profile at Week 24

    Change from baseline in serum lipid profile after 24 weeks of treatment.

    Time frame: Baseline to Week 24.

  10. Change From Baseline in Body Weight at Week 24

    Change from baseline in body weight after 24 weeks of treatment.

    Time frame: Baseline to Week 24.

  11. Change From Baseline in Waist Circumference at Week 24

    Change from baseline in waist circumference after 24 weeks of treatment.

    Time frame: Baseline to Week 24.

  12. Change From Baseline in Quality of Life Assessed by SF-36 at Week 24

    Change from baseline in quality of life evaluated using the Short Form-36 (SF-36) after 24 weeks of treatment.

    Time frame: Baseline to Week 24.

  13. Change From Baseline in Quality of Life Assessed by PCOSQ at Week 24

    Change from baseline in quality of life evaluated using the Polycystic Ovary Syndrome Questionnaire (PCOSQ) after 24 weeks of treatment.

    Time frame: Baseline to Week 24.

  14. Incidence and Severity of Adverse Events During the 24-Week Treatment Period

    Assessment of the incidence, type, and severity of adverse events occurring during the 24-week treatment period.

    Time frame: Baseline to Week 24.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Study protocol

Time frame: After publication.

Access criteria: IPD and supporting information will be available to researchers upon reasonable request (e.g., with a practical and meaningful research proposal).

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2026; primary completion for Jun 2027, 12 months later.

Of 23 phase 2 interventional studies under Polycystic Ovary Syndrome, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 29. This study's planned 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 4, 2026
First posted
May 29, 2026
StartEst.
Jun 2026
Primary completionEst.
Jun 2027
CompletionEst.
Dec 2027
Last update
May 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07616037
Responsible party
Sponsor
First posted
May 29, 2026
Start date
Jun 2026 (estimated)
Primary completion
Jun 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
May 29, 2026

Study contacts

Jingjing JIANG, MD, PhD
Contact
jiang.jingjing@zs-hospital.sh.cn
86-021-64041990

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Glucagon-Like Peptide 1

Start the discussion